We are live on
!
Find out more
SC
SMA Capital Portfolio holdings
AUM
$238M
This Fund
S&P 500
This Quarter
Est. Return
+14.62%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$238M
AUM Growth
+$6.45M
(+2.8%)
Cap. Flow
-$11.8M
Cap. Flow
% of AUM
-4.96%
Top 10 Holdings %
Top 10 Hldgs %
37.07%
Holding
184
New
89
Increased
22
Reduced
10
Closed
63
Avg Time Held
0.3
quarters
Top 10 Avg Time Held
0.9
quarters
Top 20 Avg Time Held
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$7.92M |
| 2 |
ITT
ITT
|
+$7.28M |
| 3 |
Packaging Corp of America
PKG
|
+$7.02M |
| 4 |
JB Hunt Transport Services
JBHT
|
+$6.42M |
| 5 |
Teledyne Technologies
TDY
|
+$6.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$10.3M |
| 2 |
Eaton
ETN
|
+$10.1M |
| 3 |
Caterpillar
CAT
|
+$9.48M |
| 4 |
Ferguson
FERG
|
+$8.32M |
| 5 |
Linde
LIN
|
+$7.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 55.56% |
| 2 | Consumer Discretionary | 17.53% |
| 3 | Technology | 8.66% |
| 4 | Materials | 6.15% |
| 5 | Consumer Staples | 4.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Cogent Biosciences
COGT
$5.38B
| $11.1K | ﹤0.01% |
287
+130
| +83% | +$4.55K |
2026 Q1
1 quarter
|
|
102
Ocular Therapeutix
OCUL
$1.66B
| $10.8K | ﹤0.01% |
1,098
+525
| +92% | +$4.76K |
2026 Q1
1 quarter
|
|
103
Dianthus Therapeutics
DNTH
$4.61B
| $10.7K | ﹤0.01% |
+110
| New | +$9.61K |
2026 Q2
0 quarters
|
|
104
Tarsus Pharmaceuticals
TARS
$3.42B
| $10.6K | ﹤0.01% |
169
+89
| +111% | +$5.69K |
2026 Q1
1 quarter
|
|
105
Xenon Pharmaceuticals
XENE
$3.53B
| $10.4K | ﹤0.01% |
173
+34
| +24% | +$1.89K |
2026 Q1
1 quarter
|
|
106
Mineralys Therapeutics
MLYS
$2.07B
| $10.4K | ﹤0.01% |
387
+179
| +86% | +$4.91K |
2026 Q1
1 quarter
|
|
107
Acadia Pharmaceuticals
ACAD
$3.41B
| $10.4K | ﹤0.01% |
+412
| New | +$9.06K |
2026 Q2
0 quarters
|
|
108
Erasca
ERAS
$5.61B
| $10.4K | ﹤0.01% |
+569
| New | +$8.14K |
2026 Q2
0 quarters
|
|
109
Arcus Biosciences
RCUS
$3.11B
| $10.4K | ﹤0.01% |
338
+80
| +31% | +$1.98K |
2026 Q1
1 quarter
|
|
110
Adaptive Biotechnologies
ADPT
$4.23B
| $10.4K | ﹤0.01% |
+485
| New | +$7.43K |
2026 Q2
0 quarters
|
|
111
Alkermes
ALKS
$6.81B
| $10.4K | ﹤0.01% |
+198
| New | +$7.73K |
2026 Q2
0 quarters
|
|
112
Enliven Therapeutics
ELVN
$3B
| $10.4K | ﹤0.01% |
+204
| New | +$8.66K |
2026 Q2
0 quarters
|
|
113
Ultragenyx Pharmaceutical
RARE
$1.53B
| $10.4K | ﹤0.01% |
+310
| New | +$7.7K |
2026 Q2
0 quarters
|
|
114
Celldex Therapeutics
CLDX
$2.35B
| $10.3K | ﹤0.01% |
+278
| New | +$8.98K |
2026 Q2
0 quarters
|
|
115
Relay Therapeutics
RLAY
$3.92B
| $10.3K | ﹤0.01% |
+552
| New | +$8.01K |
2026 Q2
0 quarters
|
|
116
Protagonist Therapeutics
PTGX
$9.3B
| $10.3K | ﹤0.01% |
+84
| New | +$8.77K |
2026 Q2
0 quarters
|
|
117
Vera Therapeutics
VERA
$2.15B
| $10.3K | ﹤0.01% |
+239
| New | +$8.91K |
2026 Q2
0 quarters
|
|
118
Edgewise Therapeutics
EWTX
$4.24B
| $10.2K | ﹤0.01% |
+252
| New | +$8.69K |
2026 Q2
0 quarters
|
|
119
Rhythm Pharmaceuticals
RYTM
$6.25B
| $10.2K | ﹤0.01% |
+92
| New | +$8.32K |
2026 Q2
0 quarters
|
|
120
Mirum Pharmaceuticals
MIRM
$5.58B
| $10.2K | ﹤0.01% |
+87
| New | +$8.73K |
2026 Q2
0 quarters
|
|
121
Supernus Pharmaceuticals
SUPN
$2.48B
| $10K | ﹤0.01% |
+216
| New | +$10.4K |
2026 Q2
0 quarters
|
|
|
ACLX
122
DELISTED
Arcellx
ACLX
| – | – |
-53
| Closed | -$6.08K | – |
|
123
Air Products & Chemicals
APD
$62.6B
| – | – |
-25,483
| Closed | -$7.4M | – |
|
|
APLS
124
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-294
| Closed | -$11.8K | – |
|
125
Arcutis Biotherapeutics
ARQT
$3.34B
| – | – |
-239
| Closed | -$5.63K | – |
|
Similar funds
RMC
PFA
TCM
SAM
CWM
CNBOF
NSB
CCA
SMA Capital's Q2 2026 Portfolio in Review
As of Q2 2026, SMA Capital held 184 positions worth $238M, up 2.8% from $232M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
SMA Capital withdrew a net $11.8M in Q2 2026, closing 63 positions and reducing 10 holdings. Its most notable exit was Boeing, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 56% of assets, down from 79% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, SMA Capital opened a new position in CRH worth $7.7M.
- SMA Capital's largest Q2 2026 buy was CRH: 72,000 shares worth $7.7M.
- SMA Capital added most to Ametek in Q2 2026, an estimated $2.33M increase.
- SMA Capital's biggest Q2 2026 reduction was Applied Industrial Technologies, cutting an estimated $5.83M.
- SMA Capital fully exited Boeing in Q2 2026, selling an estimated $10.3M.
- SMA Capital's ten largest holdings make up 37% of its $238M portfolio in Q2 2026.
- SMA Capital opened 89 new positions and closed 63 in Q2 2026.
- SMA Capital's portfolio value rose 2.8% quarter-over-quarter to $238M.
Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.